Introduction {#s1}
============

Methicillin resistant *Staphylococcus aureus* (MRSA) infection represents a significant cause of morbidity and mortality in both hospital and community settings. Community-associated MRSA (CA-MRSA) has become increasingly important as a cause of skin and soft tissue infections (SSTIs), particularly in patients presenting to emergency departments [@pone.0038577-Fridkin1]--[@pone.0038577-David1]. In China, HA-MRSA has been extensively studied during the past years with ST239-SCC*mec* III as the predominant clone [@pone.0038577-Chen1], [@pone.0038577-Liu1]. However, data regarding CA-MRSA was limited, with mainly reporting from children. According to these studies, the prevalence of CA-MRSA from SSTI among children was 4%, and ST59-MRSA-IV-t437 was the most common clone among CA-MRSA isolates [@pone.0038577-Wu1]. To our knowledge, no prospective clinical studies of SSTIs from adults caused by CA-MRSA have been reported in China.

The origin of the staphylococcal cassette chromosome mec (*SCCmec*) in CA-MRSA is still unknown. It is hypothesized that MRSA probably originated through the transfer of SCCmec into extant MSSA lineages with a genetic background common to MRSA clones. Therefore, it is very important to investigate the clonal structure of MSSA in each country or region, and to compare with MRSA. Moreover, as the virulence factors play an important role in the pathogenesis of community-acquired *S. aureus* infections, we also investigated the prevalence of virulence factors, including Panton-Valentine Leukocidin (*pvl*), *staphylococcal* enterotoxins C (*sec*) and *staphylococcal* enterotoxins H (*seh*) in these *S. aureus* isolates and their relationship with the genetic background.

In this study, we prospectively enrolled 501 SSTI patients from 2 teaching hospitals and 2 community hospitals in Beijing in order to investigate the prevalence, clinical and molecular characteristics of SSTIs in adults caused by *S. aureus*, with emphasis on the prevalence of CA-MRSA in adult SSTIs in China. To our surprise, we found that the livestock-associated clone ST398 in MSSA was the most prevalent with unique antimicrobial susceptibility, toxin profiles, and *agr* types.

Materials and Methods {#s2}
=====================

Enrollment of Patients and Isolation of Bacterial Isolates {#s2a}
----------------------------------------------------------

From January 2009 to August 2010, consecutive outpatients with SSTIs were prospectively enrolled at the surgical clinic and dermatological clinics in two teaching hospitals (Peking Union Medical College Hospital and Beijing Chao-Yang Hospital) and two community hospitals (Beijing Pinggu Hospital and The First Hospital Affiliated to the People's Liberation Army General Hospital). The annual visits of surgical clinic and dermatological clinics of these four hospitals ranged from 4000 to 6,000. Community acquisition of *S. aureus* was defined as a positive culture from outpatients, or inpatients within 48 hours admission if they had no risk factors for healthcare-associated acquisition such as recent hospitalization, surgery, hemodialysis, the presence of any permanent in-dwelling catheter or percutaneous medical device, or residence in a long-term care facility. A Case Report Form (CRF) completed for each patient that included demographic information, clinical symptoms, laboratory findings, the type of infection diagnosed, all antibiotic use, and clinical outcome. Specimens were collected from infection sites of every patient enrolled and cultured on blood agar and Eosin methylene blue agar. According to the colony morphology and Gram stain, rapid methods were used for *S. aureus* identification [@pone.0038577-Essers1]. MRSA isolates were initially identified using cefoxitin and oxacillin disks (30 µg, Oxoid, Cambridge) and confirmed for the presence of the *mec*A gene by polymerase chain reaction (PCR) as described previously [@pone.0038577-Zhang1].

Institutional Review Board approval was obtained before this study was begun. Written informed consent was obtained from all patients at the time of enrollment.

Antimicrobial Susceptibility Testing {#s2b}
------------------------------------

Antimicrobial susceptibility profiles of *S. aureus* isolates were determined by the agar dilution method on Mueller-Hinton agar, according to the recommendations and definitions from Clinical and Laboratory Standards Institute (CLSI) [@pone.0038577-CLSI1]. Antimicrobial agents tested included oxacillin (Sigma Chemical, St. Louis, MO), cefoxitin (Sigma Chemical, St. Louis, MO), teicoplanin (,Sanofi-aventis, Schiltigheim, France), vancomycin (Eli Lilly, Indianapolis, Indiana, United States), cefazolin (Sigma Chemical, St. Louis, MO), cefuroxime (Sigma Chemical, St. Louis, MO), ceftriaxone (Sigma Chemical, St. Louis, MO), erythromycin (Sigma Chemical, St. Louis, MO), clindamycin (Sigma Chemical, St. Louis, MO), tetracycline (Sigma Chemical, St. Louis, MO), chloramphenicol (Sigma Chemical, St. Louis, MO), gentamicin (Sigma Chemical, St. Louis, MO), trimethropim/sulphamethoxazole (SXT, Sigma Chemical, St. Louis, MO), rifampin (Sigma Chemical, St. Louis, MO), levofloxacin (Daiichi Pharmaceutical, Tokyo, Japan), tigecycline (Pfizer Pharmaceuticals, New York, USA (formerly Wyeth Pharmaceuticals, Collegeville, PA.), linezolid (Pfizer), and mupirocin (Sigma Chemical, St. Louis, MO). ATCC29213 (*S. aureus*) and ATCC29212 (*Enterococcus faecalis*) were used as quality controls.

Molecular Typing Methods {#s2c}
------------------------

All of the *S. aureus* isolates were investigated by multilocus sequence typing (MLST), *spa* typing, and accessory gene regulator (*agr*) typing. Suspensions of overnight *S. aureus* cultures on blood agar were lysed by lysostaphin for phenol-chloroform extraction of the genomic DNA, which was reconstituted in 1 ml Tris-EDTA buffer for PCR reactions. MLST was carried out as described previously [@pone.0038577-Enright1] comparing sequences of the PCR products to the MLST website (<http://saureus.mlst.net>) with clustering of related STs into clonal complexes (CCs) utilizing the online eBURST program [@pone.0038577-Feil1]. Purified PCR products of *spa* were sequenced and repeat patterns and *spa* types were assigned from the *spa* database [@pone.0038577-Koreen1]. SCC*mec* typing was performed on the CA-MRSA isolates using the multiplex PCR protocol of Oliveira et al [@pone.0038577-Oliveira1]. Nontypeable (NT) types were those differing from the standard types. International clones of SCC*mec* types I to V were used as quality controls. *agr* typing was performed as previously described method [@pone.0038577-Sakoulas1].

Detection of Toxin Genes {#s2d}
------------------------

All of the *S. aureus* isolates were screened for Panton-Valentine Leukocidin (*pvl*) gene, Toxic shock syndrome toxin 1(*tsst-1*) gene, *Staphylococcal* enterotoxin C (*sec*), *Staphylococcal* enterotoxin H (*seh*), and *Staphylococcal* exfoliative toxin (*et*) gene by PCR and electrophoresis with primers as previously described [@pone.0038577-Baba1].

Statistical Analysis {#s2e}
--------------------

The χ^2^ test with Yastes's correction or Fisher's exact test using SPSS, version 13.0 (SPSS, Chicago, IL, USA) were used for analyzing the quantitative variables. A P value of ≤0.05 was considered statistically significant. All susceptibility data and molecular test results were analyzed using WHONET software, version 5.6.

Results {#s3}
=======

Clinical and Microbiological Characteristics of SSTIs {#s3a}
-----------------------------------------------------

From January 2009 to August 2010, a total of 501 SSTI cases were enrolled in this study. Demographic details, clinical and laboratory features, and antibiotic usage are shown in [Table 1](#pone-0038577-t001){ref-type="table"}. Of all 501 cases enrolled, *S. aureus* was the most frequent organism, accounting for 32.7% (164 isolates) of all SSTIs.

10.1371/journal.pone.0038577.t001

###### Demographic and clinical features of patients with skin and soft-tissue infections (n = 501).

![](pone.0038577.t001){#pone-0038577-t001-1}

  Variables                                               n(%)
  ------------------------------------------------ ------------------
  Gender-male                                          319 (62.3)
  Age (mean±SD, years)                                 41.4±18.8
  range                                                  18--92
  Co-morbidities                                   
  Cardiovascular disease                                42 (8.4)
  Diabetes mellitus                                     35 (6.9)
  Respiratory disease                                   13 (2.6)
  Mean white blood cells (range,10^9^/L) n = 145    8.59 (4.1--26.9)
  White blood cells \>10×10^9^/L                         26.9%
  Neutrophils (mean±SD,%) n = 123                      72.7±11.0
  Hemoglobin (mean±SD, g/L) n = 140                     13.8±2.7
  Platelet (mean±SD,10^9^/L) n = 136                     236±80
  Duration of symptoms, median, Quartile, (days)   
  Fever (T\>37°C), n = 50                               3 (1--5)
  Redness, n = 157                                     6 (4--10)
  Swelling, n = 154                                    6 (4--10)
  Warmth, n = 119                                       5 (4--8)
  Pain, n = 144                                         5 (3--8)
  Pathogen identified                              
  *Single pathogen*                                
  MSSA                                                 159 (31.7)
  MRSA                                                  5 (1.0)
  Coagulase negative Staphylococcus (CoNS)             101 (20.2)
  *Streptococcus spp*                                   24 (4.8)
  *Escherichia coli*                                    21 (4.2)
  *Klebsiella spp*                                      17 (3.4)
  *Proteus spp*                                         8 (1.6)
  Others                                               66 (13.2)
  Multiple pathogens                                    25 (5.0)
  Types of skin and soft-tissue infection          
  Cutaneous abscess                                    204 (40.7)
  Impetigo                                              34 (6.8)
  Traumatic wound infection                             30 (6.0)
  Cellulitis                                            24 (4.8)
  Panaritium                                            24 (4.8)
  Furuncles, and carbuncles                             20 (4.0)
  Mastitis                                              13 (2.6)
  Lymphangitis                                          12 (2.4)
  Diabetic foot infection                               11 (2.2)
  Folliculitis                                          10 (2.0)
  Pyomyositis                                           10 (2.0)
  Others                                               108 (23.5)
  Antibiotic use only                                  153 (30.6)
  Drainage or surgical intervention only                 20 (4)
  Antibiotic with surgical intervention                328 (65.4)
  Admission to hospital                                57 (14.9)
  Admission to ICU                                      2 (0.6)
  Length of hospital stay (mean±SD, days)              16.9±14.5
  Death                                                    0

Resistance Profile of *S. aureus* Isolates {#s3b}
------------------------------------------

Of all the 164 *S. aureus,* 159 isolates were MSSA, and 5 isolates were confirmed as MRSA. All MSSA isolates were susceptible to most antibiotics tested, including cefazolin (susceptible rate, 100%), cefuroxime (100%), ceftriaxone (100%), trimethoprim/sulfamethoxazole (98.7%), levofloxacin (97.5%), and chloramphenicol (95%). However, the susceptibility of MSSA to erythromycin, clindamycin, gentamicin and tetracycline was lower with the susceptibility rates of 41.5%, 71.7%, 79.9%, and 81.0%, respectively. Additionally, 22.6% (36/159) MSSA isolates were resistant to more than 3 antimicrobial classes simultaneously. In contrast, all 5 CA-MRSA isolates were only susceptible to vancomycin, teicoplanin, linezolid, daptomycin, and tigecycline. No high level resistance to mupirocin was observed in either MSSA or CA-MRSA isolates (MIC range, 0.016--64 μg/ml).

Clinical and Molecular Characteristics of *S. aureus* {#s3c}
-----------------------------------------------------

Among the *S. aureus* infections, cutaneous abscess was the most common infection, followed by cellulitis, and impetigo. All of the *S. aureus* were analyzed by MLST, *spa* and *agr* typing. A total of 30 STs and 56 *spa* types were identified in 164 *S. aureus*. Clustering analysis by eBURST showed that these STs belonged to 16 clonal complexes (CCs)`. `Six clones (ST398, CC7, CC1, CC5, ST59, CC8) were found to be predominant types, constituting 17.1% (28/164), 12.2% (20/164), 11.6% (19/164), 8.5% (14/164), 6.7% (11/164) and 6.1% (10/164), respectively.

Overall, *agr* type I was identified as the predominant type, accounting for 64.6% (106/164) of all *S.aureus* isolates, followed by type III (14.0%), type II (13.4%), and type IV (7.9%). No significant difference on the prevalence of *pvl* was found among four *agr* types. Interestingly, none of the isolates with *agr* IV carried *sec* gene, while 59.1%--60.9% of the isolates with *agr* type II and III produced SEC (*P*\<0.001). *agr* III had higher prevalence of s*eh* gene than others (39.1% vs. 2.8%--7.7%, *P*\<0.001). In addition, the isolates with *agr* III and IV carried more *tsst*-1 genes (15.4%--17.4%) than those with *agr* I (1.9%, P = 0.005).

When evaluating only MSSA isolates, the most dominant ST was ST398 (17.6%), followed by ST7 (11.9%), ST1 (6.9%), ST59 (6.3%), ST5 (5.7%), and ST6 (5.0%). The most common spa types in MSSA were t034 (12/159, 7.5%), t796 (10/159, 6.3%), t571 (9/159, 5.7%), t127 (9/159, 5.7%), and t189 (9/159, 5.7%). The molecular characteristics for the MSSA strains are listed in [Table 2](#pone-0038577-t002){ref-type="table"}.

10.1371/journal.pone.0038577.t002

###### Molecular characteristics of 159 methicillin-susceptible *S. aureus* isolates.
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  ST        MLST-CC    No. (%) of Isolates   No. of *pvl*-positive (%)   No. of *sec-*positive (%)   No. of *seh*-positive (%)   No. of *tsst*-1-positive (%)      *agr* types (No. of isolates)                   *spa* types (No.of isolates)
  ------- ----------- --------------------- --------------------------- --------------------------- --------------------------- ------------------------------ ------------------------------------- ---------------------------------------------------------
  398         398           28 (17.6)                18 (64.3)                       3                           3                            0                       I (26), II (1), IV (1)          t034(12), t571(9), t011(4), t588(1), t4387(1), t3625(1)
  7            7            19 (11.9)                    0                           4                           0                            0                               I (19)                       t796(10), t091(6), t803(1), t309(1), t2740(1)
  943          7             1 (0.6)                     0                           0                           0                            0                                I (1)                                          t091(1)
  59          59            10 (6.3)                     8                           6                           1                            0                            I (9), II (1)                        t437(5), t441(2), t163(2), t4362(1)
  1            1            11 (6.9)                     0                           8                           8                            0                              III (11)                           t127(8), t045(1), t286(1), t701(1)
  188          1             8 (5.0)                     0                           1                           0                            1                                I (8)                                          t189(8)
  5            5             9 (5.7)                     2                           8                           0                            1                               II (9)                            t002(5), t2164(2), t062(1), t045(1)
  965          5             3 (1.9)                     2                           3                           1                            0                           II (1), III (2)                            t062(1), t127(1), t164(1)
  72           5             2 (1.3)                     1                           1                           1                            0                            I (1), II (1)                                 t148(1), t179(1)
  6            6             8 (5.0)                     1                           1                           0                            0                                I (8)                                     t701(7), t1944(1)
  25          25             7 (4.4)                     5                           5                           0                            0                                I (7)                       t078(3), t349(1), t280(1), t258(1), t1460(1)
  30          30             7 (4.4)                     7                           5                           0                            4                       I (1), II (2), III (4)                        t318(5), t964(1), t6952(1)
  285         30             1 (0.6)                     1                           1                           0                            1                               III (1)                                         t318(1)
  1320        30             1 (0.6)                     0                           0                           0                            1                               III (1)                                         t363(1)
  15          15             6 (3.8)                     0                           1                           0                            0                            II (4), IV(2)                            t084(4), t5864(1), t2119(1)
  199         15             1 (0.6)                     0                           0                           0                            0                               II (1)                                          t368(1)
  22          22             6 (3.8)                     6                           1                           0                            0                                I (6)                                     t309(5), t3622(1)
  88          88             5 (3.1)                     5                           0                           0                            0                           II (2), III(3)                  t796(1), t6497(1), t4431(1), t2616(1), t2592(1)
  121         121            4 (2.4)                     2                           0                           0                            0                               IV (4)                                t159(2), t7290(1), t1425(1)
  95          121            3 (1.9)                     2                           0                           0                            2                            I (1), IV (2)                            t164(1), t645(1), t7292(1)
  1301        121            1 (0.6)                     1                           0                           0                            0                               IV (1)                                         t3666(1)
  800         121            1 (0.6)                     0                           0                           0                            0                               IV (1)                                         t1425(1)
  20          20             2 (1.2)                     2                           2                           0                            0                                I (2)                                     t164(1), t881(1)
  45          45             2 (1.2)                     0                           2                           0                            0                                I (2)                                     t015(1), t1460(1)
  630          8             7 (4.4)                     0                           0                           0                            0                                I (7)                                t377(5), t441(1), t7291(1)
  Other    Singleton         6 (3.8)                     3                           0                           0                            0                       I (4), III (1), IV (1)          t269(1), t4431(1), t5338(1), t701(1), t015(1), t189(1)
  Total                        159                      66                          51                          14                            10                I (102), II (22), III (23), IV (12)  

The 5 patients with CA-MRSA infections occurred during work or daily activities without any identifiable risk factors. Two of them were farmers, who developed infection after trauma during work. The third was a female worker who had mastitis, the fourth was a retired woman who developed spontaneous abscesses on her check, and the last one was a 25-year old exchange student from Turkey with a spontaneous abscess on the abdomen. All of the five patients were treated with antibiotics and surgical drainage. Notably, although the antibiotics were later shown to be inactive against MRSA, all 5 patients cured 5 to 7 days after surgical intervention. The clinical and molecular characteristics of 5 CA-MRSA isolates are shown in [Table 3](#pone-0038577-t003){ref-type="table"}.

10.1371/journal.pone.0038577.t003

###### Clinical and molecular features of 5 cases with CA-MRSA infections.

![](pone.0038577.t003){#pone-0038577-t003-3}

  Case No.    Age (yr)   Gender   Residence       Infection       Resistance Profile[a](#nt101){ref-type="table-fn"}   SCC*mec* [b](#nt102){ref-type="table-fn"}    ST     MLST-CC   *spa* types   *agr* types   Toxins[c](#nt103){ref-type="table-fn"}       
  ---------- ---------- -------- ----------- ------------------- ---------------------------------------------------- ------------------------------------------- ------- --------- ------------- ------------- ---------------------------------------- ---- ----
  1              72      Female     China     Cutaneous abscess                          OEH                                              NT                        ST6      CC6        t701            I                          --                     --   --
  2              25       Male     Turkey     Cutaneous abscess                          OEL                                              IV                        ST8      CC8        t008           IV                          --                     --   \+
  3              38      Female     China        Cellulitis                              OENH                                              V                       ST59     CC59        t437            I                          \+                     --   \+
  4              68       Male      China      Wound infection                          OENRGL                                            III                      ST239     CC8        t632            I                          \+                     \+   --
  5              26       Male      China      Wound infection                          OENRGL                                             I                       ST239     CC8        t037            I                          \+                     --   --

O: oxacillin, E: erythromycin, N: clindamycin, R: tetracycline, H: chloramphenicol, G: gentamicin, L: levofloxacin.

NT: nontypable.

All of the 5 isolates were negative for TSST-1 toxin.

Comparison of Clinical Characteristics between *pvl*-positive and *pvl*-negative *S. aureus* SSTIs {#s3d}
--------------------------------------------------------------------------------------------------

Overall, 66 of 159 MSSA (41.5%) and 2 of 5 CA-MRSA (40.0%) isolates harbored the *pvl* gene. Female patients were found more commonly in *pvl*-positive group than in *pvl*-negative group (47.1% vs. 28.7%, P = 0.017), and the mean age among *pvl*-positive patients was younger than *pvl*-negative group (37.8±16.4 vs. 45.5±21.0, P = 0.014). In addition, the percentage of patients who needed surgical intervention was significantly higher in *pvl*-producing *S. aureus* SSTI than that in *pvl*-negative group (60.7% vs. 42.0%, *p* = 0.032). However, no significance was found between two groups with underlying diseases, types of infections, severity of illness and clinical outcomes, such as symptoms alleviation time and length of stay in hospital,

Comparison of Clinical and Molecular Features among the Major MLST Clones {#s3e}
-------------------------------------------------------------------------

Comparison of clinical features, toxins and *agr* types was performed among the six major clones ([Table 4](#pone-0038577-t004){ref-type="table"}). More patients in ST59 group needed incision or drainage (*p*\<0.001). Moreover, significant difference was found on antimicrobial susceptibility to erythromycin, clindamycin, tetracycline and gentamicin among the 6 CC clones (P values, 0.006--0.039, [Table 4](#pone-0038577-t004){ref-type="table"}). ST59 was more resistant to erythromycin, clindamycin and tetracycline, while CC5 was more resistant to gentamicin.

10.1371/journal.pone.0038577.t004

###### Comparison of clinical information, toxins, *agr* types and susceptibility among the major *S. aureus* clones (%)[a](#nt104){ref-type="table-fn"}.
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  Variables                       ST398 (n = 28)   CC7 (n = 20)   CC1 (n = 19)   CC5 (n = 14)   ST59 (n = 11)   CC8 (n = 10)                    *P* value
  ------------------------------ ---------------- -------------- -------------- -------------- --------------- -------------- ----------------------------------------------
  Incision or drainage                12/26            9/18          13/19           1/12           10/10           3/8         **0.001** [b](#nt105){ref-type="table-fn"}
  Antimicrobial susceptibility                                                                                                
  Erythromycin                          7               5              12             5               1              3                          **0.039**
  Clindamycin                           18              12             16             6               2              8                          **0.006**
  Tetracycline                          25              14             17             12              5              7                          **0.023**
  Gentamicin                            21              10             17             6               9              7                          **0.025**
  Toxins                                                                                                                      
  *[pvl]{.smallcaps}* ^+^           18 (64.3)           0              0           5 (35.7)       9 (81.8)        1 (10.0)     **\<0.001** [c](#nt106){ref-type="table-fn"}
  *[sec]{.smallcaps}* ^+^            3 (10.7)        4 (20.0)       9 (47.4)      12 (85.7)       6 (54.5)        2 (20.0)     **\<0.001** [d](#nt107){ref-type="table-fn"}
  *[seh]{.smallcaps}* ^+^            3 (10.7)           0           8 (42.1)       2 (14.3)        1 (9.1)        1 (10.0)     **\<0.002** [e](#nt108){ref-type="table-fn"}
  *agr* types                                                                                                                  **\<0.001** [f](#nt109){ref-type="table-fn"}
  I                                 26 (92.9)       20 (100.0)      8 (42.1)       1 (7.1)        10 (90.9)       9 (90.0)    
  II                                 1 (3.6)            0              0          11 (78.6)        1 (9.1)           0        
  III                                   0               0          11 (57.9)       2 (14.3)           0              0        
  IV                                 1 (3.6)            0              0              0               0           1 (10.0)    

Non-significant difference was found on gender, age, fever at diagnosis, contact with animals among 6 major clones.

Significant difference was found in the following comparisons: ST59 vs. CC5 (p\<0.001); ST59 vs. CC8 (p = 0.007); ST59 vs. ST398 (p = 0.003); ST59 vs. CC7 (p = 0.010); CC1 vs. CC5 (P = 0.002);

Significant difference was found in the following comparisons: ST59 vs. CC1 (p\<0.001); ST59 vs. CC5 (p = 0.042); ST59 vs. CC7 (p\<0.001); ST59 vs. CC8 (p = 0.002); CC1 vs. CC5 (P = 0.008); CC5 vs. CC7 (P = 0.007); ST398 vs. CC1 (P\<0.001); ST398 vs. CC7 (P\<0.001); ST398 vs. CC8 (P = 0.008).

Significant difference was found in the following comparisons: CC1 vs. CC5 (p = 0.033); CC1 vs. ST398 (p = 0.071); CC5 vs. CC7 (p = 0.000); CC5 vs. CC8 (P = 0.003); CC5 vs. ST398 (P\<0.001); ST59 vs. ST398 (P = 0.008).

Significant difference was found in the following comparisons: CC1 vs. ST398 (p = 0.018); CC1 vs. CC7 (p = 0.001).

Significant difference was found in the following comparisons: CC1 vs.CC5 (p = 0.015); CC5 vs. either of ST398, CC7, ST59 and CC8 (p\<0.001).

The prevalence of toxin genes varied among 6 clones. *pvl* gene was significantly more commonly detected in ST59 (81.8%, 9/11), ST398 (64.3%, 18/28) and CC5 (35.7%, 5/14) than in CC1(0/19) or CC7 (0/20) (*p*\<0.016, *p*\<0.009). In contrast, the prevalence of *sec* gene was significantly higher in CC5 (85.7%) than in CC1 (47.4%), CC7 (20%), CC8 (20%), and ST398 (10%) (P\<0.005).

Interestingly, the major six clones differed in *agr* types. *agr* type I was predominant in CC7 isolates (100%), ST398 isolates (92.9%), ST59 isolates (90.9%), and CC8 isolates (90.0%). In contrast, type II was found more prevalent in CC5 isolates (78.6%), In CC1, type III and type I accounted for 57.9% and 42.1%, respectively.

Discussion {#s4}
==========

In this study, we have three novel findings: 1) the prevalence of CA-MRSA was low among adults with SSTIs; 2) six major MSSA clones (ST398, ST7, ST1, ST59, and ST5) were responsible for SSTIs in adults in Beijing, China; 3) ST398 was the most prevalent clone among MSSA isolates.

Our previous study showed that the major HA-MSSAs belonged to the same clones (ST398, ST7, ST1, ST59, and ST5) suggesting a similar epidemiology for both hospital acquired infections and community acquired infections [@pone.0038577-Chen1]. We confirmed the presence of ST398 clone in the community [@pone.0038577-Wu1], [@pone.0038577-Du1]. Similar findings came from European researchers who found the percentage of ST398 in MRSA increased from 0 in 2002 to 30% in 2007 in Netherlands and from 13% in 2005 to 22.4% in 2008 in Germany [@pone.0038577-Huijsdens1], [@pone.0038577-Kck1], suggesting both regional variation as well as evolution in *S. aureus* ST398 over time.

ST398 is usually associated with livestock infection in pigs and people exposed to animals [@pone.0038577-Smith1], however, we did not find any association between livestock contact and ST398 infection.Whole genome sequencing of European ST398 has revealed that it lacked virulence factors such as enterotoxins and phage-encoded toxins [@pone.0038577-Schijffelen1]. Our findings are novel because we find a great number of strains (64.3%) harbored *pvl* gene.

*S. aureus* strains with *pvl* are associated with abscess formation and tissue necrosis. Our study indicated that the prevalence of *pvl* in CA-MSSA infection was high (41.5%), which was different from the previous study on children where only 4.2% of strains carried *pvl* [@pone.0038577-Wu1]. The difference in the distribution of major clones between adults and children may explain this difference in *pvl* prevalence between two studies. Similarly, past investigation has found the presence of *pvl* to be associated with a enhanced inflammatory response and localized infections [@pone.0038577-Bocchini1], which is in concurrent with our findings that more *pvl^+^* patients needed incision or drainage. Another study from New York also found the presence of PVL as a significant predictor for incision and drainage for MSSA infection, and they found patients infected with *pvl* ^+^ *S. aureus* were significantly younger than those infected with *pvl* ^−^ *S. aureus* [@pone.0038577-Kaltsas1], similar to our study.

The *agr* locus belongs to the core variable genome and is thus linked to CCs. Our molecular testing is in agreement with the findings of other studies. For example, we observed that *agr-*I was the most common type and linked to ST22, ST45, ST7, ST188, and ST59; *agr*-II was present in CC5 and CC15; *agr*-III was associated with ST1 and CC30; and *agr-4* was detected in CC121 [@pone.0038577-Holtfreter1], [@pone.0038577-Lindsay1].

In summary, this study provides the baseline information of the epidemiology and molecular characteristics of MSSA and CA-MRSA in adults with SSTIs in Beijing -- currently most disease is caused by MSSA. We identified 6 major MSSA clones that were responsible for SSTIs in the community with ST398 the most prevalent clone. Though the prevalence of CA-MRSA in Beijing is low at present, the possibility that CA-MRSA could be imported from other countries, or the potential that MSSA may acquire the SCC*mec* elements makes it important for continuous surveillance of *S. aureus* infections.
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